+43-123-13-985|info@ces.b2sg.org

Stephan Beck, Editor of Cancer Epigenetics

By | 2017-09-07T11:57:52+00:00 September 6th, 2017|News|

The Cancer Epigenetics Society is happy to announce the appointment of Dr. Stephan Beck to the Editorial Board of Cancer Epigenetics. Dr. Stephan Beck is Professor of Medical Genomics at University College London Cancer Institute (London, UK), and is one of the pioneers and a leader of the field of epigenomics. [...]

Ayalew Tefferi, Editor of Clinical Cancer Epigenetics

By | 2017-09-03T21:13:44+00:00 September 3rd, 2017|News|

The Cancer Epigenetics Society is happy to announce the appointment of Dr. Ayalew Tefferi to the Editorial Board of Clinical Cancer Epigenetics. Dr. Tefferi is Professor of Hematology and of Internal Medicine at the Mayo Clinic (Rochester, MN, USA). He also serves as a Board Review Course Faculty at MD Anderson Cancer Center, George [...]

Owen O’Connor, Editor of Clinical Cancer Epigenetics

By | 2017-07-20T11:36:48+00:00 July 20th, 2017|News|

The Cancer Epigenetics Society is happy to announce the appointment of Dr. Owen A. O'Connor to the Editorial Board of Clinical Cancer Epigenetics. Dr. O’Connor is Professor of Medicine and Experimental Therapeutics at Columbia University and Director of the Center for Lymphoid Malignancies at the Herbert Irving Comprehensive Cancer Center (New York, NY, USA). [...]

Stephen Baylin elected to the National Academy of Sciences, USA

By | 2017-07-22T09:59:46+00:00 July 17th, 2017|News|

We are proud to announce that Prof. Stephen B. Baylin, Officer at the Cancer Epigenetics Society and Editor of Cancer Epigenetics, was elected to the National Academy of Sciences, USA. This distinction is in recognition of his work in basic and applied research in the fields of epigenetics and cancer epigenetics. Prof. Baylin has [...]

The Cancer Epigenetics Society gains in popularity

By | 2017-09-04T05:41:41+00:00 July 16th, 2017|News|

The Cancer Epigenetics Society, launched only last year, continues to be ever more popular, with more people from more countries using its resources. In the social media such as LinkedIn, the Cancer Epigenetics Society has a larger size audience as that of EpiCypher (founded in 2012), EpiGentek (founded in 2005), and the Max-Planck Institute [...]

Appointment of Cigall Kadoch, Editor of Cancer Epigenetics

By | 2017-07-12T10:39:35+00:00 July 12th, 2017|News|

The Cancer Epigenetics Society is very happy to announce the appointment of Dr. Cigall Kadoch to the Editorial Board of the Cancer Epigenetics journals series. Dr. Kadoch is an expert of ATP-dependent mammalian SWI/SNF chromatin remodeling machineries, with a particular interest in locus-specific and genome-wide modulation by BAF complexes in cancer. Dr. Kadoch is Assistant [...]

Appointment of Lucy Godley, Editor of Cancer Epigenetics

By | 2017-07-12T10:40:17+00:00 July 10th, 2017|News|

The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Lucy Godley to the Editorial Board of the Cancer Epigenetics journals series. Dr. Godley is an expert of myeloid malignancies with a particular interest in DNA methylation and hydroxymethylation role in normal and neoplastic hematopoiesis. She also uses transgenic mouse models to [...]

The Cancer Epigenetics Society is a COST-Epichembio Member

By | 2017-07-04T11:47:20+00:00 July 4th, 2017|News|

The Cancer Epigenetics Society is as of July 1, 2017 a Full Member of Epichembio, an EU-funded initiative of the European Cooperation in Science and Technology (COST). Epichembio (Epigenetic Chemical Biology) regroups scientists and research institutions from 34 countries, making it one of the largest international networks in epigenetics research. It is led by [...]

The Cancer Epigenetics Society on YouTube

By | 2017-06-23T10:00:27+00:00 June 23rd, 2017|News|

The Cancer Epigenetics Society is now on YouTube with short videos relevant to cancer and/or epigenetics. The Society's first video follows the timeline of DNA-based epigenetics with several findings relevant to cancer biology or treatment. The second video highlights cancer rates in the top 50 most affected countries, showing that cancer is a global [...]

The Cancer Epigenetics Society is a UICC Member

By | 2017-06-21T14:56:54+00:00 June 20th, 2017|News|

The Cancer Epigenetics Society is as of June 15, 2017, a Full Member of the Union for International Cancer Control (UICC)! UICC is an NGO located in Geneva, Switzerland, that brings together an exclusive worldwide coalition of the major players in cancer control. It works closely with the International Atomic Energy Agency (IAEA), the [...]

Raul Urrutia, Chief Science Officer of the Cancer Epigenetics Society

By | 2017-05-19T11:28:43+00:00 May 16th, 2017|News|

The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Raul A. Urrutia as the Society's Chief Science Officer. Dr. Urrutia joins the leadership of the Cancer Epigenetics Society from the Mayo Clinic at Rochester where he holds full Professorships in Medicine, Biochemistry and Molecular Biology, and Biophysics. Dr. Urrutia is [...]

Appointment of Cheryl Arrowsmith, Editor of Cancer Epigenetics

By | 2017-05-19T11:28:43+00:00 May 3rd, 2017|News|

The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Cheryl H. Arrowsmith to the Editorial Board of Cancer Epigenetics journals series. Dr. Arrowsmith holds the Canada Chair in Structural Genomics and is Chief Scientist of the Structural Genomics Consortium (SGC) Toronto laboratories. Dr. Arrowsmith is also Professor of Medical Biophysics at the [...]

The Cancer Epigenetics Society is 1 year old!

By | 2017-05-19T11:28:43+00:00 April 28th, 2017|News|

The Cancer Epigenetics Society was on top of the world as it celebrated its 1st anniversary at the Loft restaurant and bar on the top floor of the Sofitel hotel in Vienna, Austria. The Cancer Epigenetics Society has achieved extraordinary progress in its relatively short existence so far, producing several cancer and epigenetics databases and [...]

The third annual Epigenetics Discovery Congress

By | 2017-03-21T12:39:18+00:00 March 21st, 2017|News|

The Cancer Epigenetics Society is happy to announce its partnership with the 3rd Annual Epigenetics Discovery Congress that takes place in London, from the 12th to the 13th of October 2017. The meeting will cover several aspects of epigenetics and cancer epigenetics, including transgenerational epigenetics, novel epigenetic targets, epigenetics in disease and treatment, and single [...]

Appointment of Peter-Jones, Editor-in-Chief at CE

By | 2017-05-19T11:28:43+00:00 March 13th, 2017|News|

The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Peter Jones, Chief Scientific Officer of Van Andel Research Institute (VARI, Grand Rapids, MI, USA), as co-Editor-in-Chief of the Cancer Epigenetics journal series. Dr. Jones is a world renown DNA methylation expert who was first to show that 5-azacytidine is a demethylating [...]

Appointment of Jerry Workman, Editor at CE

By | 2017-05-19T11:28:43+00:00 March 8th, 2017|News|

The Cancer Epigenetics Society is happy to announce the official appointment of Dr. Jerry Workman to the position of Editor at Cancer Epigenetics (CE) journal series. Dr. Workman is an Investigator at the Stowers Institute for Medical Research (Kansas City, MO, USA). Prior to his current position, Dr. Workman was a Fellow at Harvard University [...]

Dr. Sabine Oberhauser (30 August 1963 – 23 February 2017), here with Austria’s President Heinz Fischer

By | 2017-02-24T12:55:30+00:00 February 24th, 2017|News|

It is with great sadness that we learned of the passing of Dr. Sabine Oberhauser, Health Minister of Austria since 9/2014. Dr. Oberhauser suffered from cancer since early 2015. Not least among her many accomplishments is her commitment to fight cancer by forbiding smoking in restaurants nationwide, which should take effect in May 2018. Dr. [...]

Appointment of Sharon Dent, Editor-in-Chief at CE

By | 2017-02-24T20:57:11+00:00 February 21st, 2017|News|

The Cancer Epigenetics Society is happy to announce the official appointment of Dr. Sharon Y. R. Dent to the position of co-Editor-in-Chief of the Cancer Epigenetics (CE) journal series. Dr. Dent is Professor and holds the J. Ralph Meadows Chair of the Department of Epigenetics and Molecular Carcinogenesis at University of Texas MD Anderson Cancer [...]

Appointment of Tatiana Kutateladze, Editor at CE

By | 2017-02-21T20:42:35+00:00 January 9th, 2017|News|

The Cancer Epigenetics Society is happy to announce the official appointment of Dr. Tatiana Kutateladze to the position of Editor at Cancer Epigenetics (CE) journal series. Dr. Kutateladze is a Professor of Pharmacology at the University of Colorado School of Medicine (Aurora, CO, USA). Her research interests include studying epigenetic mechanisms, posttranslational histone modifications, and [...]

Cancer Epigenetics Society announces partnership with Treat Mesothelioma

By | 2017-01-08T20:07:52+00:00 January 8th, 2017|News|

The Cancer Epigenetics Society enters into a partnership with Treat Mesothelioma to better support mesothelioma patients worldwide. Treat Mesothelioma is dedicated to the assistance and guidance of asbestos and mesothelioma victims around the world. Treat Mesothelioma is also meant to inspire hope and to provide information and resources to help guide patients and their loved [...]

Appointment of Luciano Di Croce, Editor at CE

By | 2016-12-21T23:31:53+00:00 December 21st, 2016|News|

The Cancer Epigenetics Society is happy to announce the official appointment of Dr. Luciano Di Croce to the position of Editor at Cancer Epigenetics (CE) journal series. Dr. Di Croce is the Leader of Epigenetics Events in Cancer Group at the Centre for Genomic Regulation (CGR), an international biomedical research institute of excellence at the [...]

Appointment of Giacomo Cavalli, Editor at CE

By | 2016-12-08T18:47:09+00:00 December 8th, 2016|News|

The Cancer Epigenetics Society is happy to announce the official appointment of Dr. Giacomo Cavalli to the position of Editor at Cancer Epigenetics (CE) journal series. Dr. Cavalli is is Head of the Chromatin and Cell Biology Laboratory at the Institute for Human Genetics (Montpellier, France). He is also a Permanent Member of the EpigeneSys [...]

Appointment of Jonathan D. Licht, MD, Editor at CE

By | 2016-12-03T13:21:37+00:00 November 28th, 2016|News|

The Cancer Epigenetics Society officially appoints Dr. Jonathan D. Licht, Editor at Cancer Epigenetics (CE) journal series. Dr. Licht is Director of University of Florida Health Cancer Center (Gainesville, FL, USA), and holds the Marshall E. Rinker Sr. Foundation and David B and Leighan R. Rinker Chair. Before that, Dr. Licht was Chief of Hematology/Oncology and [...]

Appointment of Keith D. Robertson Vice-President of the Cancer Epigenetics Society

By | 2017-05-19T11:28:43+00:00 November 24th, 2016|News|

The Cancer Epigenetics Society officially appoints Dr. Keith Robertson, Officer at the Cancer Epigenetics Society and Professor of Molecular Pharmacology & Experimental Therapeutics at Mayo Clinic, Rochester (MN, USA), Vice-President of the Cancer Epigenetics Society. Keith earned his Bachelor’s degree from Cornell University, and his PhD from Johns Hopkins University. He next did his Postdoctoral training [...]

Arid1a: a fertile target in the parched anticancer drug landscape

By | 2017-05-19T11:28:44+00:00 November 17th, 2016|News|

Recent work from several labs have shown ARID1A, the helicase/ATPase-containing SWI/SNF chromatin-remodeling factor, to be mutated in several cancers, most notably in ovarian cancer (some 50% of ovarian clear-cell carcinoma). Other cancers in which ARID1A was reported to be mutated include Sézary syndrome (a leukemic form of cutaneous T cell lymphoma; ~26%), pancreatic cancer (~25%), breast [...]

Cancer Epigenetics Society announces first partnership with Mexico

By | 2017-01-08T19:02:19+00:00 November 15th, 2016|News|

The Cancer Epigenetics Society enters into a partnership with the Mexican Society of Epigenetics and Regenerative Medicine, thus marking the beginning of a program of collaborations between the Cancer Epigenetics Society and research institutions and societies in Mexico and other Latin American countries. The two societies will be working closely together to further the visibility [...]

Cancer Epigenetics Database, Experimental section: KDMi are in!

By | 2017-05-19T11:28:44+00:00 November 7th, 2016|News|

The experimental section of the Cancer Epigenetics Drug Database has been expanded to now include a fourth class of epigenetics-targeting drugs: the inhibitors of histone (lysine) demethylases or KDMi. This database currently includes data on 9 KDMi and 61 cancer cell lines. Together, the experimental section of the Cancer Epigenetics Drug Database now includes more [...]

Appointment of Susan J. Clark Editor at CE

By | 2016-11-28T14:05:04+00:00 November 2nd, 2016|News|

The Cancer Epigenetics Society officially appoints Dr. Susan J. Clark, Professor at University of New South Wales Faculty of Medicine in Sidney, Australia, Editor at Cancer Epigenetics (CE) journal series. Dr. Clark is also Group Leader of the Laboratory for Epigenetics Research, Head of the Genomics and Epigenetics Division, and Head of the Cancer Epigenetics Program at [...]

Update on the Cancer Epigenetics Database, Experimental section

By | 2017-05-19T11:28:44+00:00 August 19th, 2016|News|

We at the Cancer Epigenetics Society have lately focused our efforts on expanding the experimental datasets of the Cancer Epigenetics Drug Database with emphasis on three large classes of epigenetics-targeting drugs. These are the inhibitors of the DNA methyltransferases (DNMTi), histone deacetylases (HDACi), and histone methyltransferases (HMTi). Together, the three datasets include more than 2,500 [...]

Update on the Cancer Epigenetics Clinical Trials Database

By | 2017-05-19T11:28:44+00:00 August 17th, 2016|News|

The Cancer Epigenetics Society has continued expanding its cancer epigenetic drug clinical trial repository which now covers 500+ clinical trials. These include most if not all reported completed, ongoing, and recruiting cancer clinical trials on DNA methyltransferases (DNMTi), histone deacetylases (HDACi), histone methyltransferases (HMTi), and histone demethylases (KDMi). All databases are currently freely accessible to [...]

Empowering Cancer patients

By | 2017-05-19T11:28:44+00:00 June 28th, 2016|News|

As a member of the US National Coalition for Cancer Survivorship (NCCS), the Cancer Epigenetics Society asks our members in the States with interest in cancer treatment and survival to help support cancer advocacy in the US. One such initiative is currently undergoing under the umbrella of NCCS to provide a boost  to the bipartisan [...]

Patient’s resources at CES go local, II

By | 2016-06-21T14:20:55+00:00 June 21st, 2016|News|

We have continued to expand our country-specific resources to better cater to the needs of local patients. We now provide resources for Austria, Bulgaria, Canada, Cyprus, Ecuador, France, Greece, Nicaragua, Peru, Portugal, Russia, Slovakia, Turkey, the UK, and the US at the Advocacy & Support Group section. More resources for these and other countries are [...]

The cancer epigenetics of imprinting

By | 2016-06-21T12:15:24+00:00 June 12th, 2016|News|

Aberrations in the epigenetic phenomenon known as imprinting is a highly frequent early event in tumorigenesis (initiation of cancer) of a large number of tumors including acute myeloid leukemia (AML), Barrett's esophagus, breast cancer, chronic myeloid leukemia (CML), colorectal cancer, esophageal cancer, Ewing's sarcoma, glioma, laryngeal squamous cell carcinoma, hepatoblastoma, lung adenocarcinoma, meningioma, osteosarcoma, ovarian [...]

After cancer prevention, aspirin steps up to the plate of cancer treatment?!

By | 2016-06-05T10:38:13+00:00 June 3rd, 2016|News|

We recently reported that frequent low-dose intake of aspirin reduces the risk of developing colorectal and bile duct cancers (read it here). Now a new study from Norway shows that taking aspirin after cancer diagnosis improves survival of people diagnosed with colorectal cancer. In a collaboration between the Cancer Registry of Norway, the Norwegian Institute [...]

Walking or running away from cancer!

By | 2016-08-02T16:59:18+00:00 May 23rd, 2016|News|

Regular exercise is known to improve cardiovascular function and to reduce the risk or lessen the impact of stress, depression, high blood pressure, stroke, arthritis, osteoporosis, back pain, as well as obesity and certain forms of diabetes. An international collaborative research from the US, Sweden, Norway, Finland, France, and the UK now shows that regular [...]

Radon: radioactivity at home, the silent killer

By | 2016-05-20T13:26:35+00:00 May 20th, 2016|News|

Recent research from scientists in the US, Canada, and Europe show that residential radon can increase the risk of hematological cancers, particularly of follicular lymphoma and diffuse large B-cell lymphoma. The study analyzed data from 140,652 people in 20 US states and over nearly two decades that were grouped into low (< 74 Becquerel/m³), medium [...]

Find us on YouTube!

By | 2017-05-19T11:28:44+00:00 May 18th, 2016|News|

We proudly announce that CES has now its own YouTube channel! We have released our first video which gives a quick overview of the history of DNA chemical changes that accompany many different cellular processes, including those involved in cancer. These changes, the most common of which being DNA methylation, represents one of the most [...]

Air pollution goes beyond lung cancer!

By | 2016-05-18T15:53:21+00:00 May 17th, 2016|News|

Previous research had unsurprisingly linked high levels of fine particulate matter in breathing air (also known as PM2.5) to lung cancer. A new study links PM2.5 in breathing air to increased risk of several cancers including liver, pancreatic, and breast cancer. For example, women had an 80% increase risk of breast cancer for every 10 [...]

Of wells, pesticides, epigenetics, and bladder cancer

By | 2016-05-18T15:51:58+00:00 May 16th, 2016|News|

Exposure to high levels of arsenic was already known to increase the risk of bladder cancer. A new study from the National Cancer Institute (NIH/NCI, Bethesda, USA) of well drinking water in Maine, Vermont, and New Hampshire, found that low doses of arsenic in drinking water, presumably from contaminating pesticides, also dramatically increase risk of [...]

Patient’s resources at CES go local

By | 2016-05-18T15:51:07+00:00 May 13th, 2016|News|

After putting together resources for cancer advocacy and support groups that operate internationally, we now also provide country-specific resources that may better cater to the needs of local patients. As of today, Austria, Bulgaria, Canada, the UK, and the US figure now on our cancer Advocacy & Support group section. More support groups for these [...]

Meeting Austria’s President & First lady Fischer at Vienna’s Hofburg imperial palace

By | 2016-05-11T13:36:13+00:00 May 11th, 2016|News|

A high level meeting took place yesterday at the impressive Zeremoniensaal (room of ceremonies) at the imperial architectural masterpiece of the Hofburg palace in Vienna, Austria. Several Austrian and foreign dignitaries were present, with Dr. Heinz Fischer, President of Austria, as the guest of honor. The discussions were both informal and highly informative, and President [...]

One aspirin a day keeps the doctor at bay?

By | 2017-05-19T11:28:44+00:00 May 10th, 2016|News|

While it is now well established that low-dose, daily or frequent use of aspirin can considerably reduce the risk of cardiovascular disease and colorectal cancers, new findings from the Mayo Clinic at Rochester (MN, USA) show that aspirin can also reduce the risk of cholangiocarcinoma or bile duct cancers. In this study that included [...]

Cooling the scalp to preserve hair during chemo approved in the US:

By | 2017-05-19T11:28:44+00:00 May 9th, 2016|News|

A method that has been used for some 40 years in Europe to reduce hair loss during chemotherapy, which consists of cooling the scalp with a cold cap, has finally been approved by the United States Food and Drug Administration (FDA) for use by cancer patients in the US. The method was met for [...]